The pharmaceutical manufacturer's transformation from loss-making operations in FY24 to sustained profitability throughout FY26 represents one of the sector's most dramatic recoveries. Net sales for Q4 FY26 reached an all-time high of ₹919.96 crores, driven by robust demand across both API (Active Pharmaceutical Ingredients) and finished dosage formulations in the animal health segment. The company's operating profit before depreciation, interest, and tax (PBDIT) excluding other income climbed to ₹184.25 crores, maintaining healthy margins above 20% for the third consecutive quarter—a stark contrast to the single-digit margins witnessed in early FY25.
| Quarter | Net Sales (₹ Cr) | QoQ Growth | Net Profit (₹ Cr) | QoQ Growth | Operating Margin | PAT Margin |
|---|---|---|---|---|---|---|
| Mar'26 | 919.96 | +7.17% | 52.11 | +35.56% | 20.03% | 7.22% |
| Dec'25 | 858.41 | +0.95% | 38.44 | -29.99% | 20.46% | 5.65% |
| Sep'25 | 850.30 | +92.63% | 54.91 | +283.72% | 20.37% | 8.57% |
| Jun'25 | 441.42 | +9.89% | 14.31 | +53.54% | 11.82% | 3.98% |
| Mar'25 | 401.70 | -48.10% | 9.32 | -79.11% | 11.51% | 2.58% |
| Dec'24 | 774.03 | +109.96% | 44.61 | +1609.20% | 12.89% | 5.42% |
| Sep'24 | 368.65 | — | 2.61 | — | 10.61% | 1.72% |
Financial Performance: Margin Expansion Drives Profitability Surge
Viyash Scientific's Q4 FY26 results showcased impressive momentum across key financial parameters. Revenue growth of 7.17% quarter-on-quarter and 129.02% year-on-year reflected strong underlying demand, whilst operating margins expanded to 20.03%—the highest level since the company's restructuring. This margin improvement stemmed from operational efficiencies, favourable product mix shifts towards higher-margin formulations, and better capacity utilisation at manufacturing facilities. The company's gross profit margin reached 20.18%, up from 8.07% in the corresponding quarter last year, indicating improved pricing power and cost management.
Net profit margins expanded to 7.22% in Q4 FY26 from 2.58% in Q4 FY25, though volatility persists across quarters. The sequential 35.56% growth in consolidated net profit to ₹52.11 crores came despite a concerning spike in the effective tax rate to 47.00%—the highest in recent quarters and significantly above the normalised 28-32% range. This elevated tax burden, stemming from non-deductible expenses and timing differences, compressed bottom-line growth and raises questions about sustainability of reported profitability levels.
Interest expenses declined to ₹14.52 crores in Q4 FY26 from ₹15.13 crores in Q4 FY25, resulting in an exceptional interest coverage ratio of 12.69 times—the strongest in the company's recent history. This improvement reflects both higher operating profitability and modest debt reduction efforts. Depreciation remained elevated at ₹60.41 crores, consistent with ongoing capital expenditure programmes to expand manufacturing capacity and upgrade facilities for regulatory compliance in key export markets.
Operational Excellence: Margin Recovery Signals Turnaround
The sustained operating margin above 20% for three consecutive quarters marks a decisive break from the company's troubled operational history. Management's focus on high-margin specialty APIs and value-added formulations, coupled with operational efficiencies and better capacity utilisation, has fundamentally transformed the earnings profile. The company's ability to maintain these margins amidst raw material volatility and competitive pressures will be critical for sustaining investor confidence.
Profitability Metrics: Weak Historical Returns Persist Despite Recent Gains
Whilst Viyash Scientific's recent quarterly performance appears impressive, a deeper examination of longer-term profitability metrics reveals persistent structural weaknesses. The company's average Return on Capital Employed (ROCE) over the past five years stands at just 6.30%—significantly below the cost of capital and indicative of poor capital allocation historically. The latest ROCE of 18.12% for FY26 represents a dramatic improvement, yet remains below pharmaceutical industry leaders who consistently generate returns above 20%. Similarly, Return on Equity (ROE) averaged a meagre 5.97% over five years, though the latest reading of 15.86% shows meaningful progress.
These profitability challenges stem from years of underutilisation, pricing pressures in generic APIs, and heavy debt servicing costs. The company's average EBIT to interest coverage of just 2.15 times over the past five years highlights the burden of leverage, whilst debt to EBITDA averaged an elevated 9.75 times—well above comfortable levels for pharmaceutical manufacturers. Net debt to equity averaged 0.52, indicating moderate but manageable leverage that has been gradually improving through debt reduction and equity strengthening.
Quality Assessment: Below Average Fundamentals Constrain Rating
Viyash Scientific carries a "Below Average" quality grade from proprietary screening models, reflecting weak long-term financial performance despite recent improvements. The company's five-year sales CAGR of 14.17% and EBIT growth of 12.25% appear reasonable, but mask significant volatility including loss-making years. Average ROCE of 6.30% and ROE of 5.97% fall well short of quality benchmarks, whilst elevated debt levels and weak interest coverage historically constrain financial flexibility. The absence of dividends since 2021 further reflects management's focus on deleveraging rather than shareholder returns.
Balance Sheet Analysis: Improving but Leverage Remains Elevated
Viyash Scientific's balance sheet shows gradual improvement but continues to carry meaningful leverage. Shareholder funds stood at ₹704.47 crores as of March 2025, up from ₹656.56 crores the previous year, driven by retained earnings from the return to profitability. Long-term debt increased to ₹273.88 crores from ₹142.72 crores, reflecting fresh borrowings to fund capacity expansion and working capital requirements during the high-growth phase. Current liabilities declined to ₹505.00 crores from ₹626.99 crores, improving the current ratio and indicating better working capital management.
Fixed assets remained stable at ₹533.30 crores, representing the company's manufacturing infrastructure across multiple facilities. Current assets of ₹872.92 crores include significant inventory and receivables typical of the pharmaceutical industry's long working capital cycles. The company's book value per share of ₹28.15 compares unfavourably with the current market price of ₹252.10, resulting in a price-to-book ratio of 12.31 times—amongst the highest in the pharmaceutical sector and indicative of substantial valuation premium baked into the stock price.
| Balance Sheet Item | Mar'25 (₹ Cr) | Mar'24 (₹ Cr) | Mar'23 (₹ Cr) | Change YoY |
|---|---|---|---|---|
| Shareholder Funds | 704.47 | 656.56 | 698.78 | +7.3% |
| Long-Term Debt | 273.88 | 142.72 | 150.11 | +91.9% |
| Current Liabilities | 505.00 | 626.99 | 558.76 | -19.5% |
| Fixed Assets | 533.30 | 540.42 | 537.78 | -1.3% |
| Current Assets | 872.92 | 810.94 | 779.79 | +7.6% |
Industry Context: Animal Health Segment Offers Growth Runway
Viyash Scientific operates in the specialised animal health pharmaceutical segment, focusing on APIs and finished dosage formulations for veterinary applications. This niche positioning provides some insulation from intense competition in human pharmaceuticals, with the global animal health market expected to grow at 6-8% annually driven by rising pet ownership, livestock farming intensification, and increasing awareness of animal welfare. The company's integrated model—spanning API manufacturing to formulation development—offers vertical integration benefits and margin expansion opportunities.
However, the sector faces headwinds from pricing pressures in generic APIs, regulatory scrutiny across key export markets including Europe and North America, and raw material cost volatility. Viyash Scientific's manufacturing facilities have received approvals from major regulatory authorities, providing a competitive advantage, but maintaining compliance requires continuous capital investment. The company's global footprint, with significant export revenues, exposes it to currency fluctuations and geopolitical risks that can impact quarterly performance.
Regulatory and Market Risks: Export Dependence Creates Volatility
Viyash Scientific derives substantial revenues from regulated markets including the United States and Europe, making it vulnerable to regulatory actions, import restrictions, and pricing pressures from consolidating customer bases. Any manufacturing quality issues or compliance failures could trigger warning letters or import bans, severely impacting revenues. The company's heavy reliance on animal health APIs also concentrates risk in a relatively narrow product portfolio compared to diversified pharmaceutical peers.
Peer Comparison: Premium Valuation Despite Weaker Fundamentals
Comparing Viyash Scientific to pharmaceutical sector peers reveals a stark valuation disconnect. The company trades at a price-to-earnings ratio of 67.92 times trailing twelve-month earnings—nearly 2.5 times the sector average and significantly above most comparable companies. This premium appears unjustified given Viyash Scientific's ROE of 5.97% trails peers like Alivus Life Sciences (19.43%) and Concord Biotech (19.17%) by wide margins. The price-to-book ratio of 12.31 times also ranks amongst the highest in the sector, exceeded only by Sanofi Consumer Healthcare's 43.06 times.
Debt-to-equity of 0.52 positions Viyash Scientific in the middle of the peer group, with companies like Strides Pharma carrying similar leverage whilst others like Concord Biotech maintain net cash positions. The absence of dividend yield further distinguishes Viyash Scientific from income-generating peers, though this reflects management's prioritisation of debt reduction and growth investments over shareholder distributions. Overall, the company's valuation premium appears predicated entirely on growth expectations rather than current profitability or capital efficiency metrics.
| Company | P/E Ratio | P/BV Ratio | ROE (%) | Debt/Equity | Div Yield |
|---|---|---|---|---|---|
| Viyash Scientific | 67.92 | 12.31 | 5.97 | 0.52 | — |
| Alivus Life Sciences | 22.22 | 3.89 | 19.43 | -0.22 | 0.47% |
| Concord Biotech | 37.96 | 6.54 | 19.17 | -0.18 | 0.94% |
| Corona Remedies | 54.41 | 14.54 | 0.0 | 0.00 | — |
| Sanofi Consumer | 43.78 | 43.06 | 76.98 | -0.73 | — |
| Strides Pharma | 18.22 | 3.40 | 9.60 | 0.50 | 0.35% |
Valuation Analysis: Expensive Premium Demands Caution
Viyash Scientific's current valuation metrics flash warning signals across multiple parameters. The P/E ratio of 67.92 times significantly exceeds the pharmaceutical sector average of approximately 27 times, implying the market has priced in several years of strong earnings growth. The EV/EBITDA multiple of 23.21 times and EV/EBIT of 34.79 times similarly trade at substantial premiums to historical norms and peer averages. The PEG ratio of 1.85, whilst not extreme, suggests limited margin of safety given execution risks inherent in the company's turnaround story.
The stock's price-to-book ratio of 12.31 times compares unfavourably with the sector, particularly given Viyash Scientific's below-average ROE. For context, quality pharmaceutical companies with consistent 20%+ ROE typically trade at 4-8 times book value, making the current multiple appear stretched. The company's EV-to-sales ratio of 4.07 times also ranks towards the higher end of the sector, despite operating margins that, whilst improving, remain below industry leaders.
The proprietary valuation assessment categorises Viyash Scientific as "EXPENSIVE," a grade that has oscillated between "Fair" and "Expensive" over recent months, reflecting market uncertainty about sustainability of the earnings recovery. The stock currently trades just 6.28% below its 52-week high of ₹269.00, having rallied 51.68% from its 52-week low of ₹166.20. This strong price appreciation has compressed the risk-reward ratio, leaving limited upside unless the company can demonstrate sustained margin expansion and market share gains.
Shareholding Pattern: Promoter Consolidation Amidst Institutional Caution
The shareholding pattern reveals interesting dynamics that merit investor attention. Promoter holding stood at 61.31% as of March 2026, declining marginally by 0.10% from the previous quarter but up substantially from 52.33% in September 2025. This increase reflects promoter consolidation through the December 2025 quarter when holdings jumped 9.08 percentage points, signalling confidence in the company's turnaround prospects. The promoter group—comprising Ca Hull Investments (31.17%) and Ca Harbor Investments (30.14%)—maintains comfortable majority control with zero pledging of shares, a positive indicator of financial stability.
Foreign Institutional Investor (FII) holdings declined to 2.94% from 6.05% over the past year, representing a significant reduction of 311 basis points. This institutional exit occurred primarily in the December 2025 quarter when FII holdings dropped 275 basis points, suggesting profit-booking or concerns about valuation sustainability. Mutual fund holdings similarly contracted to 6.44% from 10.22%, with a sharp 422 basis point decline in December 2025 coinciding with the FII exodus. The simultaneous reduction by both FIIs and mutual funds raises questions about institutional conviction in the stock's long-term prospects at current valuations.
| Shareholder Category | Mar'26 | Dec'25 | Sep'25 | Jun'25 | QoQ Change |
|---|---|---|---|---|---|
| Promoter Holding | 61.31% | 61.41% | 52.33% | 52.61% | -0.10% |
| FII Holding | 2.94% | 3.16% | 5.91% | 6.15% | -0.22% |
| Mutual Fund Holding | 6.44% | 5.82% | 10.04% | 10.08% | +0.62% |
| Other DII Holdings | 1.54% | 1.54% | 2.87% | 2.90% | 0.00% |
| Non-Institutional | 27.76% | 28.06% | 28.86% | 28.26% | -0.30% |
Insurance company holdings remain at zero across all quarters, indicating no participation from this typically conservative investor class. Other domestic institutional investors (DII) held 1.54% as of March 2026, down from 2.87% in September 2025. Non-institutional holdings—primarily retail investors and non-institutional entities—stood at 27.76%, declining modestly from 28.86% six months earlier. Overall, the shareholding pattern reflects a concentration of ownership between promoters and retail investors, with limited institutional participation that could constrain liquidity and increase volatility.
Stock Performance: Exceptional Returns Driven by Turnaround Narrative
Viyash Scientific's stock has delivered extraordinary returns across most timeframes, significantly outperforming both the Sensex benchmark and the broader pharmaceutical sector. Over the past year, the stock generated returns of 49.00% compared to the Sensex's decline of 7.23%, resulting in alpha of 56.23 percentage points. This outperformance accelerated over shorter periods, with three-month returns of 16.23% (alpha of 25.28%) and one-month returns of 21.61% (alpha of 25.69%) reflecting growing investor enthusiasm following the strong quarterly results.
The stock's two-year return of 116.67% and three-year return of 221.76% place it amongst the top performers in the pharmaceutical sector, driven by the dramatic operational turnaround from loss-making operations to sustained profitability. However, longer-term performance reveals inconsistency, with five-year returns of negative 7.27% underperforming the Sensex by 59.23 percentage points. This longer-term underperformance reflects the company's troubled history prior to the recent recovery, including years of margin compression and debt-servicing challenges.
| Period | Stock Return | Sensex Return | Alpha | Sector Return |
|---|---|---|---|---|
| 1 Day | 10.14% | 0.16% | +9.98% | — |
| 1 Week | 12.27% | 0.95% | +11.32% | — |
| 1 Month | 21.61% | -4.08% | +25.69% | — |
| 3 Months | 16.23% | -9.05% | +25.28% | — |
| 6 Months | 5.42% | -12.04% | +17.46% | — |
| 1 Year | 49.00% | -7.23% | +56.23% | 12.76% |
| 2 Years | 116.67% | 1.77% | +114.90% | — |
| 3 Years | 221.76% | 22.01% | +199.75% | — |
| 5 Years | -7.27% | 51.96% | -59.23% | — |
Technical indicators support the bullish momentum, with the stock trading above all key moving averages including the 5-day (₹226.87), 20-day (₹215.32), 50-day (₹204.43), 100-day (₹206.38), and 200-day (₹202.79) moving averages. The overall technical trend classification of "BULLISH" since May 13, 2026, reinforces positive momentum, with multiple indicators including MACD, Bollinger Bands, KST, and On-Balance Volume all flashing bullish signals. However, the stock's high beta of 1.34 indicates elevated volatility relative to the broader market, with one-year volatility of 41.19% placing it in the "HIGH RISK HIGH RETURN" category.
Investment Thesis: Turnaround Story Priced to Perfection
Viyash Scientific presents a classic case of a successful operational turnaround that has been enthusiastically embraced by the market—perhaps too enthusiastically. The company's proprietary investment score of 63 out of 100 places it firmly in "HOLD" territory, reflecting the tension between improving fundamentals and stretched valuations. The score breakdown reveals the complexity: whilst near-term financial trends are rated "OUTSTANDING" and technical indicators remain "BULLISH," the company's "BELOW AVERAGE" quality grade and "EXPENSIVE" valuation assessment constrain the overall rating.
The investment thesis rests on several key pillars. First, management has demonstrated capability in executing the turnaround, with operating margins consistently above 20% for three quarters and interest coverage reaching record levels. Second, the animal health pharmaceutical segment offers structural growth opportunities with less intense competition than human pharmaceuticals. Third, the company's integrated manufacturing model and regulatory approvals provide competitive advantages in serving regulated markets.
However, significant concerns temper enthusiasm. The 68x P/E ratio leaves virtually no room for disappointment, with any margin pressure, regulatory setback, or demand slowdown likely to trigger sharp corrections. Historical profitability metrics remain weak despite recent improvements, with five-year average ROCE of 6.30% and ROE of 5.97% indicating the turnaround is recent rather than established. The institutional exodus—with FII and mutual fund holdings declining sharply—suggests sophisticated investors have concerns about sustainability at current valuations.
Key Strengths & Risk Factors
KEY STRENGTHS
- Margin Transformation: Operating margins sustained above 20% for three consecutive quarters, up from single digits in early FY25
- Revenue Momentum: Net sales reached record ₹919.96 crores in Q4 FY26, with 129% YoY growth demonstrating strong demand
- Interest Coverage: Exceptional 12.69x coverage ratio reflects improved profitability and reduced financial stress
- Niche Positioning: Focus on animal health APIs and formulations provides differentiation from crowded human pharma segment
- Regulatory Approvals: Manufacturing facilities approved by major global regulators enable access to high-value markets
- Promoter Confidence: Increased promoter holding to 61.31% with zero pledging signals management conviction
- Technical Strength: Stock trading above all moving averages with bullish indicators supporting momentum
KEY CONCERNS
- Extreme Valuation: 68x P/E and 12.3x P/BV ratios significantly exceed sector averages and leave no margin for error
- Weak Historical Returns: Five-year average ROCE of 6.30% and ROE of 5.97% indicate recent turnaround not yet established
- Institutional Exodus: FII and mutual fund holdings declined sharply, with 311 bps and 378 bps reductions respectively over one year
- Tax Rate Volatility: Q4 FY26 effective tax rate of 47% raises questions about sustainability of reported profitability
- Elevated Leverage: Debt-to-equity of 0.52 and increasing long-term debt constrain financial flexibility
- High Volatility: Beta of 1.34 and 41% annualised volatility indicate significant price risk
- No Dividend: Absence of shareholder distributions since 2021 reflects ongoing capital constraints
Outlook: What to Monitor Going Forward
POSITIVE CATALYSTS
- Sustained operating margins above 20% for multiple quarters demonstrating operational stability
- Further debt reduction improving interest coverage and financial flexibility
- New product launches or regulatory approvals expanding addressable market
- Improvement in ROE/ROCE metrics towards sector averages (15-20% range)
- Return of institutional investor interest with FII/MF holding stabilisation
RED FLAGS TO WATCH
- Margin compression below 18% indicating pricing pressure or cost inflation
- Revenue growth deceleration or sequential declines suggesting demand weakness
- Regulatory warnings or compliance issues at manufacturing facilities
- Further institutional selling or promoter stake reduction
- Sustained high tax rates above 35% compressing net profitability
Investors should closely monitor quarterly margin trends, as any compression below the 18-20% range would signal that the turnaround is losing momentum. Revenue growth sustainability across both domestic and export markets will be critical, particularly given the elevated valuation multiples. Balance sheet improvement through debt reduction and working capital optimisation should remain priorities, whilst any return to dividend payments would signal management confidence in cash flow sustainability.
The Verdict: Impressive Turnaround, But Valuation Demands Caution
Score: 63/100
For Fresh Investors: Avoid initiating positions at current valuations. The 68x P/E ratio and 12.3x P/BV multiple price in several years of perfect execution, leaving minimal margin of safety. Wait for a meaningful correction (20-25%) or sustained evidence of margin expansion and market share gains before considering entry. The stock's high volatility (41% annualised) will likely provide better entry opportunities.
For Existing Holders: Consider booking partial profits to lock in the exceptional 49% one-year gains and 222% three-year returns. The institutional exodus and stretched valuations suggest limited near-term upside despite strong operational momentum. Retain a core position only if you have high conviction in management's ability to sustain 20%+ margins and deliver consistent earnings growth over the next 2-3 years. Set a trailing stop-loss at 15% below current levels to protect gains.
Fair Value Estimate: ₹180-200 (29-21% downside from current levels), based on 45-50x normalised FY27 earnings estimates assuming sustained profitability but accounting for execution risks and sector valuation norms.
Note– ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. The stock market involves risks, including the potential loss of principal invested.
